CDT Equity (CDT) Capital Expenditures (2024 - 2025)
CDT Equity's (CDT) quarterly Capital Expenditures came in at -$7000.0 in Q3 2025, down 117.07% YoY from $41000.0 in Q3 2024, and down 800.0% on a QoQ basis from $1000.0 in Q2 2025.
CDT Equity (CDT) Capital Expenditures (2024 - 2025) Analysis & Trends
CDT Equity (CDT) has 2 years of Capital Expenditures data on file, last reported at -$7000.0 in Q3 2025.
- Quarterly Capital Expenditures fell 117.07% year-over-year to -$7000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $398000.0 (changed N/A YoY) and the FY2024 annual result came in at $51000.0, changed N/A from the prior year.
- Capital Expenditures eased to -$7000.0 in Q3 2025, from $1000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $404000.0 in Q1 2025 to a low of -$7000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 404,000.00 |
| Mar 31, 2025 | 404,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Sep 30, 2024 | 41,000.00 |